Furthermore, inhibitors with activity against both Fes and Flt3-ITD kinases in vitro blocked Flt3-ITD+ AML cell growth in the low to mid-nanomolar range, suggesting that dual inhibition of this key AML driver mutation and the proximal effector kinase Fes may provide added benefit in this type of AML. This evidence concerns the gene FES and acute myeloid leukemia.